TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05247450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation therapy (FES-t)
Description: Functional electrical stimulation therapy (FES-t) that will use a multichannel device (MyndSearch device).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Conventional physiotherapy is the current standard of care for rehabilitation of C5 palsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Conventional physiotherapy is the current standard of care for rehabilitation of C5 palsy
Study: NCT06554106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation Group
Description: All patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises. In addition to the study group, NMES will be applied to the upper trapezius muscle for 30 minutes 5 days a week for 4 weeks. Neuromuscular Electrical Stimulation (NMES) applications will be performed with a Compex 3 (Compex Medical SA, Ecublens, Switzerland) model, portable and programmable electrostimulator unit in rehabilitation mode and under the supervision of an expert physiotherapist experienced in the device and application. The NMES program will be applied with a 4-channel device with a functional stimulation capacity of 120 mA, pulse duration 400 μs and pulse frequency 150 Hz.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises.
Study: NCT04826263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: All patients will be instructed to follow a home exercise program for 3 weeks. Patients will be informed about the exercises by giving an exercise sheet describing the exercises and an exercise diary prepared to mark the days they exercise. The home exercise program will include previously recommended exercises such as Achilles tendon and plantar fascia stretching and toe curl exercises. Patients will be instructed to perform these exercises 10 repetitions each and 3 times per day for three weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: All patients will be instructed to follow a home exercise program for 3 weeks. Patients will be informed about the exercises by giving an exercise sheet describing the exercises and an exercise diary prepared to mark the days they exercise. The home exercise program will include previously recommended exercises such as Achilles tendon and plantar fascia stretching and toe curl exercises. Patients will be instructed to perform these exercises 10 repetitions each and 3 times per day for three weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Description: Patients in the LLLT group will receive gallium-aluminum-arsenide (Ga-Al-As) low-level laser treatment with Chattanooga Vectra Genisys Transport model (Chattanooga Group) with a wavelength of 850 nm and a power of 100 mW. The LLLT treatment will be applied 3 times a week, a total of 10 sessions. A maximum energy density of 5.6 j/cm2 will be reached by delivering a continuously increasing dose of energy to each tender spot for one minute. The LLLT will be performed with patients in the prone position and will be applied to 5 points on the plantar fascia by positioning the laser head perpendicular to the treatment area.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Description: Patients in the ESWT group will receive treatment with a radial ESWT system (EMS Swiss Dolor Clast), which transforms kinetic energy into a shock wave, which is then applied to the target tissue with pressure varying from 1 to 10 bar and penetrating up to 40 mm. The ESWT treatment will be administered to the patients once a week for three weeks, for a total dose of 2000 mJ/mm2 pulse per application. ESWT will be applied to the patients in prone position with their foot inverted. Ultrasound gel will be applied to the patient's heel The area of tenderness will be palpated and 1000 shock wave impulses were applied to this area, and 1000 pulses will be applied over the plantar fascia.
Study: NCT04855240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-044 Dose A
Description: Oral dose of ACP-044 Dose A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-044 Dose B
Description: Oral dose of ACP-044 Dose B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose of placebo
Study: NCT05547087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VN-0200
Description: VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VN-0200
Description: VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VN-0200
Description: VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VN-0200
Description: VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VN-0200
Description: VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VN-0200
Description: VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VN-0200
Description: VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VN-0200
Description: VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VN-0200
Description: VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VN-0200
Description: VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.
Study: NCT05779228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mode Switching Training
Description: Wear of colored lenses for 1 hr, 5 times per day, for 5 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mode Switching Training
Description: Wear of colored lenses for 1 hr, 5 times per day, for 5 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mode Switching Training
Description: Wear of colored lenses for 1 hr, 5 times per day, for 5 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mode Switching Training
Description: Wear of colored lenses for 1 hr, 5 times per day, for 5 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mode Switching Training
Description: Wear of colored lenses for 1 hr, 5 times per day, for 5 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mode Switching Training
Description: Wear of colored lenses for 1 hr, 5 times per day, for 5 days
Study: NCT05429580

Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic acid
Description: given intravenous tranexamic acid

Intervention type: DRUG
Group type: OTHER
Intervention: Tranexamic acid
Description: given intravenous tranexamic acid

Intervention type: OTHER
Group type: OTHER
Intervention: 5% Dextrose
Description: given placebo.

Intervention type: OTHER
Group type: OTHER
Intervention: 5% Dextrose
Description: given placebo.
Study: NCT05353114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).
Description: The 3D foot scan becomes a movile app that recommends a specific size and model of therapeutic footwear according to the measurements
Study: NCT05100771

Intervention type: OTHER
Intervention: Pediatric brain MRI
Description: Routine brain MRI with automated quantitative information (brain volumetry and T1 relaxometry)
Study: NCT04770558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Exergame
Description: The one-to-one supervised training session consists of 10 min warm-up exercise, 40 min interactive exergame, and 10 min cool-down exercise. Both physical (muscle strength, coordination and balance in lower limbs) and cognitive functions (visuospatial, attention, short-term memory, calculation, reaction and executive function) will be trained through the interactive exergame.
Study: NCT04803864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Orally 100mg, 3 times per week for 2 weeks First dose administered immediately after successful PCI.
Study: NCT05340478

Intervention type: BEHAVIORAL
Intervention: Intensive Transdiagnostic Cognitive Behavioral Therapy
Description: cognitive behavioral treatment that addresses multiple anxiety problems simultaneously and delivered in a massed format over one weekend
Study: NCT06162273

Intervention type: DEVICE
Intervention: IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company
Description: Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.
Study: NCT04981964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: both groups received conventional physiotherapy training program, for one hour, three sessions per week, for three successive months, based on neurodevelopmental treatment, composed of approximation of the upper and lower limbs in a regular and rhythmic manner, facilitation of righting, equilibrium and protective reactions, training of postural stability and equal weight shift especially on the affected side, stretching, strengthening exercises for upper and lower limbs and back muscles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: both groups received conventional physiotherapy training program, for one hour, three sessions per week, for three successive months, based on neurodevelopmental treatment, composed of approximation of the upper and lower limbs in a regular and rhythmic manner, facilitation of righting, equilibrium and protective reactions, training of postural stability and equal weight shift especially on the affected side, stretching, strengthening exercises for upper and lower limbs and back muscles
Study: NCT05340946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anaesthesia
Description: intraoperative general anaesthesia followed by postoperative IV patient analgesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anaesthesia
Description: patient received spinal followed by continuous ultrasound guided femoral never block.
Study: NCT04625400

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bronchoscope
Description: Bronchoscopy in Assessment of Patients With Post-intubation Tracheal Stenosis.
Study: NCT04757571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine 20 mg tablet plus standard therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet plus standard therapy
Study: NCT04889248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training with Powerbreath IMT device.
Description: Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.~Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.~The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax.
Study: NCT05982639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two lung ventilation
Description: The intervention do not involve a drug or device. It will be compared two different approaches to ventilate the lungs during the procedure . In this arm both lungs will be ventilated inserting a disposable trocar into the pleural cavity, and insufflating CO2 into the thoracic cavity via an insufflator. The insufflation pressure and the flow rate will be set as 8 mmHg and 10 l.min-1, of the cavity with CO2. The insufflator will be adjusted for cavity pressure in 8mmHg and flow of 10L/min.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: one lung ventilation
Description: In this arm only one lung (the contralateral lung) will be ventilated using a Carlens type orotracheal tube
Study: NCT05263570

Intervention type: DRUG
Intervention: Standard Therapy
Description: Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
Study: NCT06005558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 100 ml 0.9% Nacl over 20 minutes, followed by continuous infusion of normal saline for 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 100 ml 0.9% Nacl over 20 minutes, followed by continuous infusion of normal saline for 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue low dose
Description: A bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue low dose
Description: A bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue high dose
Description: A bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue high dose
Description: A bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
Study: NCT05961683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV plus software
Description: interventions received by infants studied after placing them on ventilator using NIV plus software
Study: NCT05870319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: intravenous (IV) infusion (Q2W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2 intravenous (IV) infusion (Q3W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 intravenous (IV) infusion (Q3W) 4cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2 intravenous (IV) infusion (Q3W) 4cycles
Study: NCT06380764

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater Occipital Nerve Block
Description: The occipital artery was localized, while the patient was setting with flexed neck, at the point of meeting of the medial third and the lateral two-thirds of a line drawn extending from the ipsilateral mastoid process to the external occipital protuberance and the GON was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline.~For assurance of GON localization, pressure was applied and the resultant tenderness indicated the site of the nerve. Injection procedure was performed as distal injection at the site of nerve localization and proximal injection was performed at 1.5 cm lateral to the sagittal plane and 3 cm below to the level of the external occipital protuberance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral suboccipital intramuscular injection
Description: Sub-occipital intramuscular injection of the prepared solution was carried out on both sides while the patient was setting with maximally flexing the neck to expose these muscles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Blood Patch
Description: Patients showed manifestations of block failure within 24-h after block, received lumbar Epidural blood patch under non-invasive monitoring in the theater. Patient was positioned in the lateral decubitus position, lumbar area was sterilized and the epidural space previously used for receiving the previous neuraxial anesthesia was identified. Fifteen ml of venous blood was obtained aseptically and slowly injected while patient was monitored for the extent of pain severity until complete pain relief.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 10 mL Injection
Description: Placebo drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: Lidocaine is the main drug used in the interventions as it was injected to achieve bilateral block or intramuscular infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: Lidocaine is the main drug used in the interventions as it was injected to achieve bilateral block or intramuscular infiltration
Study: NCT05121298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upadacitinib 15mg/day
Description: Patients will receive upadacitinib 15mg/day and continue to receive same doses of MTX until 24 weeks. If patients achieve a European League Against Rheumatism (EULAR) moderate response or a Disease Activity Score 28 (DAS28-CRP) ≤3.2 at 12 weeks, and a DAS28-CRP of \<2.6 at 24 weeks, they will discontinue MTX, and continue upadacitinib until 48 weeks.
Study: NCT06508528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a 12-week growth mindset intervention
Description: This is a 12-week growth mindset intervention for the nursing students during clinical rotation practice. It aims at promoting the core self-evaluation and professional sefl-efficacy for them. The intervention has 12 themes, with each intervention lasting 15 to 20 minutes. Intervention will be carried out through a combination of online and offline methods.

Intervention type: OTHER
Group type: OTHER
Intervention: Hospital mentoring
Description: The control group will receive guidance from the hospital. Including self-regulation of stress, self-protection in clinical practice, and so on
Study: NCT05059704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit Class Training
Description: Station 1 will include tasks for warm-up specific for upper extremity, station 2 will include shoulder exercises, station 3 will include elbow exercises, station 4 will include wrist exercises and station 5 will include hand activities and functional training. Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual Task specific training
Description: Variables such as speed, or/and resistance will progressively increase in diﬃculty according to each patient's ability.
Study: NCT04689919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG Oral Tablet
Description: The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
Study: NCT05729113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction technique
Description: Distribution of an anti-stress ball before the moment of cannulation of the vascular access and instructing to place it in hand opposite the limb of the vascular access
Study: NCT05919784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Description: The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).
Study: NCT02016495

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium plus alpha-lipoic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05448989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% atropine 5+3
Description: A method for myopia control using high-concentration atropine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% atropine 5+3
Description: A method for myopia control using high-concentration atropine
Study: NCT06552832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAVEAT
Description: Brief manualized parent-child psychotherapy
Study: NCT05494463

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miller blade
Description: After laryngoscopy with Macintosh blade patient will be evaluated in laryngoscopy with Miller blade
Study: NCT06527625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cultural Arts Program
Description: 9-session group art program using Chinese calligraphy as the channel for gaining emotional awareness and facilitating expression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual provided in local community aged care centres
Study: NCT05355935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral tablet.
Study: NCT04661423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Automated Monitoring System
Description: The patient will be monitored with conventional monitoring devices as well as the MultiSense patch.